MDxHealth sees return to positive EBITDA, reaffirms 2026 sales guidance
MDxHealth said it expects tissue growth to accelerate in the second half and to return to positive adjusted EBITDA as it exits 2026, while reaffirming fiscal 2026 sales guidance of $110 million-$115 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.